| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1377949 | Bioorganic & Medicinal Chemistry Letters | 2006 | 4 Pages |
Abstract
The 3-benzimidazol-2-yl-1H-indazole scaffold was developed as an alternate scaffold for our receptor tyrosine kinase (RTK) inhibitor program. In exploring the SAR of this series, it was discovered that a subset of these compounds potently inhibit the enzyme c-ABL. The SAR of these compounds is described.
Graphical abstractThe 3-benzimidazol-2-yl-1H-indazole scaffold was developed for our receptor tyrosine kinase (RTK) inhibitor program. In exploring the SAR of this series, a subset of these compounds were found to potently inhibit the enzyme c-ABL. The SAR of these compounds is described.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Christopher M. McBride, Paul A. Renhowe, Thomas G. Gesner, Johanna M. Jansen, Julie Lin, Sylvia Ma, Yasheen Zhou, Cynthia M. Shafer,